CCO Management Series
Minimizing Barriers and Maximizing Response: Strategies and Tools for Frontline Providers Caring for Patients With Chronic Hepatitis C
Interactive Case Challenges
Management of a Patient With Hepatitis C Genotype 1 Infection Who Relapsed After a Course of Standard Interferon and Ribavirin
Program Director:
Gregory T. Everson, MD, FACP
- Tiffany A. Geahigan, PA-C, CCRC
|
|
|
 Join Tiffany A. Geahigan, PA-C, CCRC, in choosing the optimal treatment strategies for an obese black patient with hepatitis C genotype 1 who relapsed after a course of standard-dose interferon alfa and ribavirin. Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss factors associated with response and nonresponse in hepatitis C
- Describe strategies for the management of HCV-infected patients with multiple negative predictors of response
- Describe the manifestations and management strategies for interferon-induced thyroid abnormalities
|
Retreatment in a Patient Failing Previous Therapy
|
|
|
Anne Croghan, MN, ARNP, discusses treatment options and predictors of response for patients relapsing on previous peginterferon/ribavirin therapy. Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize factors associated with favorable and unfavorable responses to peginterferon/ribavirin in patients with chronic hepatitis C
- Discuss the role of maintenance therapy in patients with chronic hepatitis C
- Recount the advantages and disadvantages of high-dose induction therapy and extension therapy in patients with hepatitis C
|
Treatment of an HCV-Infected Patient With Advanced Disease (coming soon)
- Gregory T. Everson, MD, FACP
|
|
|
|
Virtual Presentations
Hepatitis C: Maximizing Therapeutic Response
Program Director:
Michael W. Fried, MD
|
|
 Michael W. Fried, MD, discusses strategies to tailor HCV treatment according to a patient’s individual response. Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount key data regarding HCV treatment dosing and its relationship to treatment outcomes
- Describe the effects of discontinuing therapy on overall treatment responses
- Discuss strategies to tailor HCV treatment to individual patient responses
|
Hepatitis C: Maximizing Therapeutic Response
 |
|
Michael W. Fried, MD, discusses strategies to tailor HCV treatment according to a patient’s individual response.
Format: Microsoft PowerPoint (.ppt) | File size: 1,106 KB
|
Therapy for Difficult-to-Treat HCV Patients: Relapsers and Nonresponders (coming soon)
Management of Hepatitis C in Advanced Liver Disease Patients (coming soon)
Interactive Tools
HCV Drug Dose and Response
an Interactive Decision Support Tool
 |
|
Interested in understanding more about HCV treatment dosing strategies with peginterferon and ribavirin and the factors involved in determining the best strategy for your patient?
This tool enables you to select specific patient characteristics that have been associated with treatment response in controlled studies and then view a convenient graphical summary of the key data from those studies. You can also print the data and/or download slides. Practical calculators that can be used to understand HCV drug dosing and the impact on treatment response are also included.
Format: Adobe Flash | File size: 397 KB
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|